Lantheus Holdings, Inc. $LNTH Holdings Raised by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lifted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 42.7% in the third quarter, HoldingsChannel reports. The firm owned 35,954 shares of the medical equipment provider’s stock after purchasing an additional 10,757 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Lantheus were worth $1,844,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Hantz Financial Services Inc. lifted its stake in Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in shares of Lantheus during the second quarter valued at approximately $26,000. First Horizon Corp acquired a new stake in shares of Lantheus during the third quarter valued at approximately $26,000. Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus in the 2nd quarter valued at approximately $36,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in Lantheus during the 3rd quarter worth approximately $59,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on LNTH. Mizuho increased their target price on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Truist Financial increased their price objective on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Citizens Jmp lifted their target price on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research note on Tuesday. William Blair raised shares of Lantheus from a “market perform” rating to an “outperform” rating in a research report on Thursday. Finally, Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $78.83.

Lantheus Stock Performance

LNTH stock opened at $75.43 on Friday. The firm has a 50 day moving average of $67.97 and a two-hundred day moving average of $60.01. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $111.29. The company has a market capitalization of $5.00 billion, a price-to-earnings ratio of 31.69 and a beta of -0.08. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. The firm had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. Lantheus’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

More Lantheus News

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 beat — Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected, with improved margins and ROE, supporting near‑term earnings power. MarketBeat: Q4 results
• Positive Sentiment: Analyst upgrade — William Blair upgraded LNTH to “Outperform,” a vote of confidence that can support buying interest. Street Insider: William Blair upgrade
• Positive Sentiment: Price target increase — Citizens Jmp raised its price target to $78, which can provide a modest valuation floor for the shares. American Banking News: PT raise
• Neutral Sentiment: Earnings call / disclosure materials posted — Full earnings call transcript, slide deck and press release are available for investors to dig into segment details and management commentary. Seeking Alpha: Earnings call transcript
• Negative Sentiment: Cautious FY‑2026 guidance — Management set EPS guidance of $5.00–$5.25 (consensus ~5.16) and revenue guidance $1.4B–$1.5B (consensus ~$1.5B). The midpoint and lower end of the revenue range are slightly light versus Street expectations, creating near‑term uncertainty on growth trajectory. GlobeNewswire: Q4 results & guidance
• Negative Sentiment: Intraday selling on mixed setup — despite the beat and upgrades, investors pulled back on the guidance and booked profits after a big run from the stock in the prior year. WTOP: Earnings snapshot

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.